Highest-materiality recent filing
Novavax shareholders elect directors, approve say-on-pay by narrow margin
All three Class I director nominees (Jacobs 43.5M, Alton 41.4M, Rodgers 42.6M) elected.
Novavax Q1 revenue $140M, net loss $9M; Pfizer Matrix-M deal adds $30M upfront
Total revenue $140M, down 79% YoY; prior-year included $603M non-cash APA close-out.
Novavax Q4 net income $18M, full-year profit $440M; Pfizer Matrix-M license deal
Q4 2025 revenue $147M (+67% YoY); net income $18M vs $81M loss in Q4 2024.
Novavax licenses Matrix-M adjuvant to Pfizer for up to $500M milestones plus royalties
Upfront payment of $30M in Q1 2026; eligible for up to $500M in milestones ($70M development, $180M sales per field).
Novavax presents strategic update at J.P. Morgan; 2025 results pending
Preliminary financial results for year ended Dec 31, 2025 are being finalized and subject to change.
Novavax Q3 net loss $202M, revenue down to $70M; raises FY2025 revenue guidance
Total revenue $70M, down 18% YoY from $85M; product sales (Nuvaxovid) $0 vs $38M.
FDA approved transfer of U.S. marketing authorization for Nuvaxovid from Novavax to Sanofi on Nov 3, 2025.
Assignment fee $15M, parcel sale $20M, asset sale $24.8M; total $59.8M from AstraZeneca.
Novavax completes Nuvaxovid EU marketing authorization transfer to Sanofi; triggers $25M milestone
European Commission approved transfer of Nuvaxovid EU marketing authorization from Novavax CZ to Sanofi Winthrop Industrie.
FDA approves Novavax's Nuvaxovid 2025-2026 COVID-19 vaccine for high-risk populations
Approved for adults 65+ and high-risk individuals 12-64; only protein-based non-mRNA COVID-19 vaccine available in U.S. for 2025-2026 season.
Novavax issues $225M 4.625% convertible notes due 2031, exchanges $148.7M of 2027 notes
Issued $225M principal of 4.625% Convertible Senior Notes due 2031; initial conversion price ~$11.14 (27.5% premium).
Novavax issues $225M in 4.625% convertible notes due 2031, refinancing 2027 notes
Issued $225M of 4.625% Convertible Senior Notes due 2031; exchanged ~$148.7M of 2027 notes and raised ~$49.7M new cash.
Novavax Q2 revenue $239M; net income $107M; $175M Sanofi milestone from FDA BLA approval
Total revenue of $239M, down 42% YoY, includes $175M milestone from Nuvaxovid BLA approval.
Elected Class III directors Rachel K. King, John W. Shiver, and Charles W. Newton (each with majority 'For' votes).
Novavax Phase 3 CIC & flu vaccine candidates show robust immune responses, well tolerated
COVID-19-Influenza Combination (CIC) and stand-alone flu vaccine candidates induced 2.4-5.7-fold immune responses over baseline.
Novavax eliminates COO role; John Trizzino to depart June 20, 2025
COO position eliminated; John Trizzino's employment terminated effective June 20, 2025.
Novavax receives FDA approval for Nuvaxovid COVID-19 vaccine; triggers $175M Sanofi milestone
FDA approves BLA for Nuvaxovid for COVID-19 in adults 65+ and high-risk individuals 12-64.
Novavax Q1 revenue $667M, net income $519M; raises FY guidance to $975M-$1.025B
Total revenue $667M vs $94M YoY; net income $519M vs net loss $148M.
Novavax amends Takeda COVID vaccine pact; gets $19.5M upfront, tiered royalties
Upfront payment $19.5M from Takeda; $5M creditable against royalties for Takeda FY2024.
Novavax appoints Charles W. Newton to Board, increasing size to nine members
Board expanded from 8 to 9 members; Charles W. Newton appointed as Class III director effective April 25, 2025.
Novavax says COVID-19 vaccine BLA approvable; FDA requests additional clinical data as PMC
Believes BLA is approvable based on FDA conversations as of PDUFA date April 1 and through April 23.
Novavax says FDA missed PDUFA deadline for COVID-19 vaccine BLA; still awaiting decision
FDA's April 1 PDUFA date passed; no official decision received as of April 2, 2025.
Novavax terminates Canada COVID vaccine APA, to recognize $576M revenue in Q1 2025
Canada terminated APA effective March 7, 2025, citing Novavax's failure to obtain regulatory approval for vaccine from Biologics Manufacturing Centre by Dec 31, 2024.
Novavax Chair James Young retires; Margaret McGlynn named successor; John Shiver joins board
James Young, PhD resigned as Board Chair effective March 10, 2025, after 15 years on the board.
Novavax issues 2025 financial guidance and strategic update at TD Cowen conference
Provided 2025 revenue framework and combined R&D/SG&A expense guidance for 2025 and 2026.
Q4 2024 revenue $88M (vs $291M YoY); full year $682M (vs $984M). Product sales $50M vs $251M.
Novavax reaffirms full year 2024 guidance; presents at J.P. Morgan conference
Reaffirmed full year 2024 financial guidance, no specific figures provided.
Novavax completes $200M sale of Czech manufacturing campus to Novo Nordisk
Total purchase price $200M; $180M cash at close, $10M paid Sept 2024, $10M escrow for 12 months.
Novavax amends Australia COVID vaccine agreement; cancels doses, credits $31M, extends to 2029
Amendment #5 cancels certain COVID vaccine doses scheduled for delivery Q4 2023 through Q4 2025.
Novavax subsidiary agrees to sell Czech manufacturing campus to Novo Nordisk subsidiary for $200M
Total purchase price $200M; $10M credit from September 2024 and $10M escrow released 12 months post-closing.
Novavax to present corporate update at Jefferies London Healthcare Conference
Presentation scheduled for November 20, 2024; no specific numbers or details included in the filing or attached exhibit.
Novavax Q3 revenue $85M, net loss $121M; FDA lifts clinical hold on combo vaccine
Total revenue $85M (down from $187M YoY); net loss $121M vs $131M; cash $924M as of Sept 30.
FDA lifts clinical hold on Novavax's COVID-flu combo and standalone flu vaccines
FDA removed clinical hold on Novavax's IND for CIC and stand-alone influenza candidates on Nov 11.
Novavax settles UK COVID vaccine supply dispute, agrees to pay $123.8M refund
Settlement with UK Health Security Agency resolves all claims related to the Amended and Restated Supply Agreement.
FDA placed clinical hold on Novavax's IND for CIC and standalone influenza vaccine candidates.
Novavax clarifies it has not updated FY2024 guidance after analyst report
Analyst report published Oct 1, 2024 cited management discussions on US COVID-19 vaccine market.
Novavax Q2 net income $162M on $415M revenue; Sanofi partnership boosts cash to $1.1B
Q2 2024 total revenue $415M (vs. $424M Q2 2023); net income $162M (vs. $58M).
Novavax stockholders approve director elections, advisory pay, and equity plan share increases
Stockholders elected Class II directors Richard Douglas, Margaret McGlynn, and David Mott with majorities (approx. 25.5M, 22.9M, 23.1M For).
Novavax FDA sets PDUFA date April 2025 for COVID vaccine BLA; plans EUA sales for 2024-2025
FDA completed BLA filing review; PDUFA goal date set for April 2025 for COVID-19 vaccine.
Novavax President of R&D Filip Dubovsky to retire effective June 30, 2024
Dubovsky retires as President, R&D effective June 30, 2024.
Novavax and Sanofi enter $500M upfront collaboration; Sanofi buys $68.8M in stock
$500M non-refundable upfront payment; up to $700M in milestones for COVID products.
Novavax signs $1.3B Sanofi deal; Q1 revenue $94M, net loss $148M; removes going concern
Co-exclusive licensing with Sanofi includes $500M upfront, ~$70M equity, up to $700M milestones plus royalties per product.
Novavax reduces stockholder meeting quorum from majority to one-third
Board adopted Amended and Restated By-Laws effective April 22, 2024.
Novavax settles manufacturing dispute with Fujifilm for $42M, releases claims
Paid $42M on March 25, 2024 to Fujifilm, resolving $68.6M disputed installments under prior cancellation agreement.
Novavax Q4 revenue $291M, full-year net loss $545M; guides 2024 revenue $800M-$1B
Q4 2023 revenue $291M (down 18% YoY); full-year revenue $984M (down 51% from $2B in 2022).
Novavax settles Gavi arbitration: pays $75M upfront, $400M deferred through 2028
Initial cash payment of $75M to Gavi made Feb 20; deferred payments of $80M/yr through 2028 total $400M.
Novavax to cut ~12% of global workforce; expects $4-7M restructuring charge in Q1 2024
Board approved ~12% global workforce reduction (9% of FTEs; remainder contractors/consultants).
Novavax reaffirms FY2023 combined R&D and SG&A expense guidance of $1.15-1.25B
Reaffirmed full-year 2023 combined R&D and SG&A expenses anticipated between $1.15B and $1.25B.
Novavax reaches $47M settlement in principle to resolve securities class action
Company agreed to pay $47M into settlement fund; expects D&O insurance to fund it.
Novavax appoints John Trizzino as President & COO; Herrmann to retire, Casey to join as CLO
John Trizzino appointed President and COO (new role), effective November 20, 2023; base salary increased by $50k to $570,000.
determined to eliminate the position of Chief Operating Officer, and terminate the employment of John Trizzino with the Company effective as of June 20, 2025.
appointed Charles W. Newton. to the Board, effective on such date, to fill the resulting vacancy and to serve as a Class III director
On March 10, 2025, James F. Young, Ph.D. resigned from the Board of Directors (the “Board”) of Novavax, Inc. (the “Company”), effective as of March 10, 2025.
On March 10, 2025, the Board appointed John W. Shiver, Ph.D. to the Company’s Board, effective on such date, to fill the vacancy created by Dr. Young’s resignation and to serve as a Class III director for a term expiring at the Company’s 2025 annual meeting of stockholders and until his successor is duly elected and qualified or until his earlier death, resignation or removal.
Margaret G. McGlynn was appointed to serve as the Chairperson of the Board to succeed Dr. Young.
On May 20, 2024, Filip Dubovsky notified Novavax, Inc. (the “Company”) of his decision to retire as President, Research and Development, effective as of June 30, 2024.
John A. Herrmann III informed the Company of his intention to retire from his role as Chief Legal Officer and Corporate Secretary, effective December 8, 2023.
Dr. Gregory M. Glenn, M.D. notified Novavax Inc. (the “Company”) of his decision to retire as President, Research and Development, effective as of March 31, 2023.
On February 28, 2023, Dr. Gregory M. Glenn, M.D. notified Novavax Inc. (the “Company”) of his decision to retire as President, Research and Development, effective as of March 31, 2023.
Mr. Jacobs will succeed Stanley C. Erck, who provided the Board with notice on January 5, 2023 of his decision to retire as President and Chief Executive Officer and as a member of the Board, in each case effective as of January 23, 2023.
the Board of Directors (the “Board”) of Novavax, Inc. (the “Company”) approved the appointment of John C. Jacobs, age 56, as President and Chief Executive Officer and a member of the Board, effective as of January 23, 2023.
On October 29, 2022, the Board of Directors (the “Board”) of Novavax, Inc. (the “Company”) voted to increase the size of the Board from seven members to eight members and to appoint Richard J. Rodgers to the Board to fill the resulting vacancy, effective as of October 29, 2022.
Max materiality 0.90 · Median 0.70 · Most common event other_material